XGX Pharma ApS: Financial statements 2025
CVR: 32289290
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
XGX Pharma ApS (CVR 32289290) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 32,338,381 and a net result of DKK 16,074,119 compared with DKK 4,453,433 the year before. That is an increase of 101.7% compared with the year before. Equity in the 2025 report amounted to DKK 30,787,180. The solvency ratio was 55.9%.
- Gross Profit
- DKK 32,338,381
- Profit/Loss
- DKK 16,074,119
- Equity
- DKK 30,787,180
- Total Assets
- DKK 55,114,885
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 32.3 mio. | 16.1 mio. | 30.8 mio. | 0 |
| 2024 | - | 16 mio. | 4.5 mio. | 18.7 mio. | 4 |
| 2023 | - | 8.1 mio. | 461 t. | 14.3 mio. | 5 |
| 2022 | - | 2.9 mio. | -1.8 mio. | 13.8 mio. | 4 |
| 2021 | - | 14.5 mio. | 7.2 mio. | 13.2 mio. | 3 |
Official annual report
How creditworthy is XGX Pharma ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
XGX Pharma ApS has won the tender "Amgros 2026 1.1216.a" issued by Amgros I/S worth 19,794,473 DKK.
XGX Pharma ApS has won the tender "Amgros 2026 1.1202.a" issued by Amgros I/S worth 383,606,720 DKK.
XGX Pharma ApS has won the tender "Amgros 2026 1.604.a" issued by Amgros I/S worth 501,367,776 DKK.
XGX Pharma ApS has won the tender "Amgros 2026 1.201.a" issued by Amgros I/S worth 286,787,957 DKK.
As of July 21, 2025, KPMG P/S has been appointed auditor of XGX Pharma ApS.
As of July 21, 2025, Kreston CM Statsautoriseret Revisions interessentskab has stepped down as auditor of XGX Pharma ApS.
As of July 21, 2025, Per Anders Larnholt has joined the board of directors of XGX Pharma ApS.
As of July 21, 2025, Johan Frödin has joined the board of directors of XGX Pharma ApS.
As of July 21, 2025, Mohammad Sohail Asghar has left the board of directors of XGX Pharma ApS.
As of July 21, 2025, Lars Karlsmose has left the board of directors of XGX Pharma ApS.
About XGX Pharma ApS
XGX Pharma ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2009. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named VITAL PHARMA NORDIC ApS and VITAL PHARMA NORDIC HOLDING ApS. The management consists of Jens-Nikolaj Schøier. The board consists of Per Anders Larnholt (chair) and Johan Frödin. The company is owned by Unimedic Pharma AB. The company has 6 employees (2026). In 2025, the company reported a gross profit of DKK 32,338,381 and a net result of DKK 16,074,119 compared with DKK 4,453,433 the year before. Equity in the 2025 report amounted to DKK 30,787,180.